Syndrome X

Jump to navigation Jump to search

Chronic stable angina Microchapters

Acute Coronary Syndrome Main Page

Home

Patient Information

Overview

Historical Perspective

Classification

Classic
Chronic Stable Angina
Atypical
Walk through Angina
Mixed Angina
Nocturnal Angina
Postprandial Angina
Cardiac Syndrome X
Vasospastic Angina

Differentiating Chronic Stable Angina from Acute Coronary Syndromes

Pathophysiology

Epidemiology and Demographics

Risk Stratification

Pretest Probability of CAD in a Patient with Angina

Prognosis

Diagnosis

History and Symptoms

Physical Examination

Test Selection Guideline for the Individual Basis

Laboratory Findings

Electrocardiogram

Exercise ECG

Chest X Ray

Myocardial Perfusion Scintigraphy with Pharmacologic Stress

Myocardial Perfusion Scintigraphy with Thallium

Echocardiography

Exercise Echocardiography

Computed coronary tomography angiography(CCTA)

Positron Emission Tomography

Ambulatory ST Segment Monitoring

Electron Beam Tomography

Cardiac Magnetic Resonance Imaging

Coronary Angiography

Treatment

Medical Therapy

Revascularization

PCI
CABG
Hybrid Coronary Revascularization

Alternative Therapies for Refractory Angina

Transmyocardial Revascularization (TMR)
Spinal Cord Stimulation (SCS)
Enhanced External Counter Pulsation (EECP)
ACC/AHA Guidelines for Alternative Therapies in patients with Refractory Angina

Discharge Care

Patient Follow-Up
Rehabilitation

Secondary Prevention

Guidelines for Asymptomatic Patients

Noninvasive Testing in Asymptomatic Patients
Risk Stratification by Coronary Angiography
Pharmacotherapy to Prevent MI and Death in Asymptomatic Patients

Landmark Trials

Case Studies

Case #1

Syndrome X On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Syndrome X

CDC onSyndrome X

Syndrome X in the news

Blogs on Syndrome X

to Hospitals Treating Syndrome X

Risk calculators and risk factors for Syndrome X

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

The terms Syndrome X or Metabolic syndrome X may also be referring to metabolic syndrome.

Synonyms and key words: Microvascular angina

Overview

(Cardiac) syndrome X is angina (chest pain) associated with objective evidence of myocardial ischemia in the absence of epicardial coronary artery disease. The disorder has been hypothesized to be a disorder of the coronary microvasculature rather than the large caliber epicardial coronary arteries.

Pathophysiology

In a large percentage of patients, there is microvascular dysfunction. Specifically, the microvasculature cannot dilate to accomadate increased blood flow during exertion to meet the needs of myocardial metabolism.

Several other pathophysiologic mechanisms have been proposed with variable data to support them:

Adenosine as a Cause of Chest Pain

An Extension of Dysautonomias

Syndrome X has been associated with dysautonomias and with a greater frequency of autonomic symptoms such as tachycardia, dyspnea, dizziness, and paresthesias [1]. It has therefore been hypothesized that Syndrome X may be an extension of abnormalities of the autonomic nervous system.

"Female Pattern" of Atherosclerosis

It has also been speculated that although the coronary arteriogram may appear normal, there may in fact be diffuse atherosclerosis present in what has been termed "a female pattern" of disease.

Enhanced Pain Sensitivity

It has also been hypothesized by some physicians that patients with Syndrome X have "enhanced pain sensitivity".

Panic Disorder

Approximately one third of patients with angina pectoris and normal coronary arteries are diagnosed with panic disorder [2].

Epidemiology and Demographics

Syndrome X occurs more often in young women. Some studies have found an increased risk of other vasospastic disorders in syndrome X patients, such as migraine and Raynaud's phenomenon.

Natural history, complications, and prognosis

Syndrome X does not appear to be associated with an excess of major coronary events.

Risk Factors

Female gender and left ventricular hypertrophy are associated with an excess risk of Syndrome X. The onset in women often occurs after menopause.

Other Conditions to Distinguish Syndrome X From

Syndrome X should be distinguished from Prinzmetal's angina, a disorder which involves spasm of the main epicardial coronary arteries. Syndrome X involves dysfunction of the downstream microvasculature. Syndrome X must also be distinguished from esophageal spasm.

Diagnosis

Syndrome X is a diagnosis of exclusion. The diagnostic criteria are as follows:

ESC Guidelines for investigation in patients with Syndrome X (DO NOT EDIT)[3]

Class I

1. Resting echocardiogram in patients with angina and normal or non-obstructed coronary arteries to assess for presence of ventricular hypertrophy and/or diastolic dysfunction. (Level of Evidence: C)

Class IIb

1. Intracoronary acetylcholine during coronary arteriography, if the arteriogram is visually normal, to assess endothelium-dependent coronary flow reserve, and exclude vasospasm. (Level of Evidence: C)

2. Intracoronary ultrasound, coronary flow reserve, or FFR measurement to exclude missed obstructive lesions, if angiographic appearances are suggestive of a nonobstructive lesion rather than completely normal, and stress imaging techniques identify an extensive area of ischaemia. (Level of Evidence: C)

Treatment

The mainstay of treatment in patients with Syndrome X are calcium channel blockers, such as nifedipine and diltiazem. Other therapies include:

ESC Guidelines for pharmacological therapy to improve symptoms in patients with Syndrome X (DO NOT EDIT)[3]

Class I

1. Therapy with nitrates, beta blockers, and calcium channel blockers alone or in combination. (Level of Evidence: B)

2. Statin therapy in patients with hyperlipidaemia. (Level of Evidence: B)

3. ACE inhibitors in patients with hypertension. (Level of Evidence: C)

Class IIa

1. Trial of therapy with other anti-anginals including nicorandil and metabolic agents. (Level of Evidence: C)

Class IIb

1. Aminophylline for continued pain, despite Class I measures. (Level of Evidence: C)

2. Imipramine for continued pain, despite Class I measures. (Level of Evidence: C)

References

  1. Katon W, Hall ML, Russo J, Cormier L, Hollifield M, Vitaliano PP; et al. (1988). "Chest pain: relationship of psychiatric illness to coronary arteriographic results". Am J Med. 84 (1): 1–9. PMID 3337115.
  2. Mukerji V, Beitman BD, Alpert MA, Lamberti JW, DeRosear L, Basha IM (1987). "Panic disorder: a frequent occurrence in patients with chest pain and normal coronary arteries". Angiology. 38 (3): 236–40. PMID 3565851.
  3. 3.0 3.1 Fox K, Garcia MA, Ardissino D, Buszman P, Camici PG, Crea F; et al. (2006). "Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology". Eur Heart J. 27 (11): 1341–81. doi:10.1093/eurheartj/ehl001. PMID 16735367.

Review Articles

Template:SIB


Template:WikiDoc Sources